We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12
Avg Time Held
2.9 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
2.4 quarters

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN icon
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APGE icon
1
DELISTED
Apogee Therapeutics
APGE
$122M 3.95%
1,842,515
+1,161,414
+171% +$50.7M
2023 Q3
2 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$13.8B
$101M 3.25%
730,209
+15,000
+2% +$2.05M
2023 Q1
4 quarters
ARGX icon
3
argenx
ARGX
$52.2B
$86.5M 2.79%
219,824
+66,620
+43% +$25.8M
2023 Q4
1 quarter
PCVX icon
4
Vaxcyte
PCVX
$10.8B
$82.8M 2.67%
1,212,703
-77,262
-6% -$5.35M
2022 Q4
5 quarters
LEGN icon
5
Legend Biotech
LEGN
$3.63B
$69.8M 2.25%
1,243,795
+681,195
+121% +$41.1M
2022 Q4
5 quarters
PEN icon
6
Penumbra
PEN
$12.6B
$66M 2.13%
295,892
+73,100
+33% +$18.1M
2022 Q4
5 quarters
MRVI icon
7
Maravai LifeSciences
MRVI
$985M
$62.6M 2.02%
7,221,960
+2,181,325
+43% +$14.8M
2023 Q2
3 quarters
VKTX icon
8
Viking Therapeutics
VKTX
$3.4B
$58.5M 1.88%
+713,100
New +$31.7M
2024 Q1
0 quarters
XENE icon
9
Xenon Pharmaceuticals
XENE
$3.37B
$56.3M 1.81%
1,308,011
-339,300
-21% -$15.6M
2022 Q4
5 quarters
IRTC icon
10
iRhythm Holdings
IRTC
$3.48B
$56.1M 1.81%
483,257
-84,900
-15% -$9.54M
2022 Q4
5 quarters
ALGN icon
11
Align Technology
ALGN
$10.1B
$55.5M 1.79%
169,252
+22,939
+16% +$6.73M
2022 Q4
5 quarters
GH icon
12
Guardant Health
GH
$22.3B
$51.1M 1.65%
2,476,804
+1,717,876
+226% +$36.8M
2023 Q2
3 quarters
CGON icon
13
CG Oncology
CGON
$5.58B
$49.6M 1.6%
+1,130,235
New +$46.2M
2024 Q1
0 quarters
KROS icon
14
Keros Therapeutics
KROS
$223M
$48.8M 1.57%
737,379
-381,582
-34% -$22.6M
2023 Q2
3 quarters
TMDX icon
15
Transmedics
TMDX
$2.68B
$45.4M 1.46%
614,531
+496,830
+422% +$40.9M
2023 Q3
2 quarters
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
$45.1M 1.45%
+2,668,549
New +$39.7M
2024 Q1
0 quarters
GKOS icon
17
Glaukos
GKOS
$9.83B
$42.5M 1.37%
450,676
+207,916
+86% +$18.6M
2022 Q4
5 quarters
FNA icon
18
DELISTED
Paragon 28, Inc.
FNA
$41.6M 1.34%
3,365,609
+3,785
+0.1% +$45K
2023 Q1
4 quarters
ISRG icon
19
Intuitive Surgical
ISRG
$149B
$40.1M 1.29%
+100,500
New +$38M
2024 Q1
0 quarters
DAWN icon
20
DELISTED
Day One Biopharmaceuticals
DAWN
$35.9M 1.16%
2,173,704
-2,041,869
-48% -$30.6M
2022 Q4
5 quarters
FDMT icon
21
4D Molecular Therapeutics
FDMT
$682M
$33.5M 1.08%
+1,052,485
New +$26.9M
2024 Q1
0 quarters
KIDS icon
22
OrthoPediatrics
KIDS
$572M
$32.3M 1.04%
1,107,770
– –
2022 Q4
5 quarters
KRYS icon
23
Krystal Biotech
KRYS
$9.73B
$31.5M 1.02%
177,089
-19,111
-10% -$2.65M
2022 Q4
5 quarters
RLAY icon
24
Relay Therapeutics
RLAY
$3.88B
$31.1M 1%
+3,743,999
New +$36.5M
2024 Q1
0 quarters
IRWD icon
25
Ironwood Pharmaceuticals
IRWD
$598M
$30.4M 0.98%
+3,489,843
New +$42.3M
2024 Q1
0 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.